Hemophilia



PF-06741086 Long-term Treatment in Severe Hemophilia


Condition:   Hemophilia A or B
Intervention:   Biological: PF-06741086
Sponsor:   Pfizer
Not yet recruiting


Understanding Hemophilia A and B Drug Dosage Administration Patterns


Conditions:   Hemophilia A;   Hemophilia B
Interventions:   Drug: Hemophilia B standard half-life;   Drug: Hemophilia B extended half-life;   Drug: Hemophilia A standard half-life;   Drug: Hemophilia A extended half-life
Sponsor:   Pfizer
Terminated


Gene Modified autoHST for Type A or B Hemophilia


Conditions:   Hemophilia A;   Hemophilia B
Interventions:   Biological: YUVA-GT-F801;   Biological: YUVA-GT-F901
Sponsor:   Shenzhen Geno-Immune Medical Institute
Enrolling by invitation


Hemophilia Mobile App Usability Pilot


Condition:   Hemophilia
Intervention:   Device: SureSource Engage application
Sponsors:   Healthcare Innovation Technology Lab;   Bayer
Active, not recruiting


Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies


Condition:   Hemophilia
Intervention:   Other: Non interventional study
Sponsor:   Nantes University Hospital
Recruiting


PF-06741086 Multiple Dose Study in Severe Hemophilia


Condition:   Hemophilia A or B
Intervention:   Biological: PF-06741086
Sponsor:   Pfizer
Recruiting


Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B


Condition:   Hemophilia B
Intervention:  
Sponsor:   Dimension Therapeutics
Completed


Drug Use Investigation of Kovaltry in Hemophilia A Patients


Condition:   Hemophilia A
Intervention:   Drug: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973)
Sponsor:   Bayer
Recruiting


National Survey of People With Haemophilia in Portugal


Condition:   Haemophilia
Intervention:  
Sponsors:   University of Minho;   Hospital Sao Joao;   Portuguese hemophilia association and other congenital coagulopathies
Completed


Effectiveness of Psychological Interventions in Haemophilia


Condition:   Haemophilia
Interventions:   Behavioral: Hypnosis;   Behavioral: Cognitive-Behavioral Therapy
Sponsors:   University of Minho;   Hospital Sao Joao
Not yet recruiting


A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors


Condition:   Hemophilia A
Intervention:   Drug: Emicizumab
Sponsors:   Hoffmann-La Roche;   Chugai Pharmaceutical
Active, not recruiting


The Hemophilia Ultrasound Project


Conditions:   Hemophilia A;   Hemophilia B
Interventions:   Other: Ankle and Knee Ultrasound Joint Assessment;   Other: Ankle and Knee Magnetic Resonance Imaging
Sponsors:   University of Miami;   Shire
Recruiting


Does the Thrombin Generation Test Performed During the Pharmacokinetic Profile of the Substitutive Factor VIII Bring Benefits to the Personalized Treatment of Pediatric Patients and Adult Hemophilia A Patients Under Prophylaxis ?


Condition:   Hemophilia
Interventions:   Device: Chronometric method;   Device: Chromogenic method;   Device: Thrombin generation test (TGT)
Sponsor:   Brugmann University Hospital
Recruiting


Evaluation of a Simple Pharmacokinetic Tool (myPKFiT™) to Guide Personalized Factor VIII Dosing in Patients With Hemophilia


Condition:   Hemophilia A
Intervention:  
Sponsors:   Victor Blanchette;   St. Paul's Hospital;   Montreal Children's Hospital of the MUHC;   Queen's University;   University Hospital, Motol;   University Hospital Brno;   Royal Children's Hospital;   Sydney Children's Hospitals Network;   Royal Prince Alfred Hospital, Sydney, Australia
Enrolling by invitation


Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A


Condition:   Severe Haemophilia A
Intervention:   Drug: Pharmacokinetic based dosage change
Sponsors:   Hampshire Hospitals NHS Foundation Trust;   University of Wales Cardiff United Kingdom (UK);   Uppsala University
Completed


Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B


Condition:   Hemophilia B
Intervention:   Genetic: AAVrh10FIX
Sponsor:   Dimension Therapeutics
Completed


Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A."


Condition:   Hemophilia A
Intervention:   Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Sponsor:   Bayer
Active, not recruiting


An Open-label Extension Study of an Investigational Drug, ALN-AT3SC, in Patients With Moderate or Severe Hemophilia A or B


Conditions:   Hemophilia A;   Hemophilia B
Intervention:   Drug: ALN-AT3SC
Sponsor:   Alnylam Pharmaceuticals
Active, not recruiting


National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A


Condition:   Hemophilia A
Intervention:   Behavioral: Educational Package
Sponsor:   Hampshire Hospitals NHS Foundation Trust
Completed


Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B


Condition:   Hemophilia B
Intervention:   Genetic: AAV5-hFIX
Sponsor:   UniQure Biopharma B.V.
Active, not recruiting


Platelet Function in Patients With Hemophilia A


Condition:   Hemophilia A
Intervention:  
Sponsors:   Boston Children’s Hospital;   Baxter Healthcare Corporation
Enrolling by invitation


Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A


Condition:   Haemophilia A
Intervention:   Biological: Optivate 500IU
Sponsor:   Bio Products Laboratory
Terminated


A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A


Condition:   Hemophilia A
Intervention:   Biological: BAY94-9027
Sponsor:   Bayer
Active, not recruiting


Inhibitor Development in Patients With Hemophilia A Undergoing Surgery


Condition:   Hemophilia A
Intervention:  
Sponsors:   Emory University;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI)
Completed


Study of Biostate® in Children With Hemophilia A


Condition:   Hemophilia A
Intervention:   Biological: Biostate
Sponsors:   CSL Behring;   Parexel
Completed

Refine Your Search Advanced Search